AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28588109 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD, DA, ET
Number of subjects: 210
Study 25205534 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-dose INR self-control (VLO group)
Number of subjects: 1571
Study 25205534 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-dose INR self-control (VLT group)
Number of subjects: 1571
Study 25205534 — intervention group
Group type: COMPARATOR
Intervention: Low-dose INR self-control (LOW group)
Number of subjects: 1571
Study 23810482 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 33345
Study 23810482 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 33345
Study 23810482 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (age > 65 years)
Number of subjects: 33345
Study 23810482 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 33345
Study 20807260 — intervention group
Group type: EXPERIMENTAL
Intervention: Dill extract (1%)
Number of subjects: 0
Study 19285585 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics process
Number of subjects: 0
Study 17023847 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy
Number of subjects: 56
Study 17023847 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 56
Study 17023847 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy (for L4-L5 herniation)
Number of subjects: 56
Study 12781108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine dependence assessment using the modified Fagerström Test for Nicotine Dependence (FTND)
Number of subjects: 2647
Study 12781108 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 2647
Study 15570231 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion at a rate of 6 mL/h
Number of subjects: 50
Study 15570231 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 50
Study 10406050 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with IALTE
Number of subjects: 19
Study 10406050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers of infants with IALTE
Number of subjects: 19
Study 10406050 — intervention group
Group type: COMPARATOR
Intervention: Mothers of control infants
Number of subjects: 19
Study 10406050 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of perceived 'difficultness' in infants with IALTE
Number of subjects: 19
Study 7494801 — intervention group
Group type: EXPERIMENTAL
Intervention: CR tablet A (acetaminophen A)
Number of subjects: 0
Study 7494801 — intervention group
Group type: EXPERIMENTAL
Intervention: CR tablet B (acetaminophen B)
Number of subjects: 0
Study 7494801 — intervention group
Group type: COMPARATOR
Intervention: Both CR tablets A and B
Number of subjects: 0
Study 2399001 — intervention group
Group type: EXPERIMENTAL
Intervention: Honan intraocular pressure (IOP) reducer
Number of subjects: 30
Study 2399001 — intervention group
Group type: COMPARATOR
Intervention: Digital pressure
Number of subjects: 30
Study 748569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 71
Study 748569 — intervention group
Group type: COMPARATOR
Intervention: Ethambutol
Number of subjects: 71
Study 31955525 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-EGFR antibody plus chemotherapy
Number of subjects: 203
Study 31290518 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF‐B (biscuits supplemented with antioxidant dietary fiber isolated from spent coffee grounds)
Number of subjects: 0
Study 31290518 — intervention group
Group type: EXPERIMENTAL
Intervention: SC‐FOS‐B (combination of spent coffee grounds and fructooligosaccharides)
Number of subjects: 0
Study 31290518 — intervention group
Group type: COMPARATOR
Intervention: TB (traditional recipe without added fiber)
Number of subjects: 0
Study 28759967 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor learning exercise program on compensatory STS maneuvers (n = 51)
Number of subjects: 97
Study 28759967 — intervention group
Group type: COMPARATOR
Intervention: Low‐intensity motor placebo activity (n = 46)
Number of subjects: 97
Study 28759967 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor learning exercise program on compensatory STS maneuvers
Number of subjects: 97
Study 25820243 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 38
Study 25820243 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 38
Study 24176144 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 1502
Study 22669291 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-7246 in UGT2B17*2/*2 carriers
Number of subjects: 0
Study 22669291 — intervention group
Group type: COMPARATOR
Intervention: MK-7246 in UGT2B17*1/*1 wild-type genotype
Number of subjects: 0
Study 22669291 — intervention group
Group type: EXPERIMENTAL
Intervention: M3-to-MK-7246 AUC ratio in UGT2B17*2/*2 carriers
Number of subjects: 0
Study 22669291 — intervention group
Group type: EXPERIMENTAL
Intervention: Apparent half-life of MK-7246
Number of subjects: 0
Study 19415540 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 115
Study 19415540 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 115
Study 17330306 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis self-management program in primary care
Number of subjects: 31
Study 15222284 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosaic bioprosthesis
Number of subjects: 139
Study 15222284 — intervention group
Group type: COMPARATOR
Intervention: Perimount bioprosthesis
Number of subjects: 139
Study 11123737 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual morphine 0.1 mg x kg(‐1)
Number of subjects: 29
Study 11123737 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 0.1 mg x kg(‐1)
Number of subjects: 29
Study 9882058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepitel dressing
Number of subjects: 76
Study 9882058 — intervention group
Group type: COMPARATOR
Intervention: Flamazine treatment (standard silver sulfadiazine cream)
Number of subjects: 76
Study 8031483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentrust (manual toothbrush)
Number of subjects: 25
Study 8031483 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Complete (manual toothbrush)
Number of subjects: 25
Study 8031483 — intervention group
Group type: EXPERIMENTAL
Intervention: Interplak (mechanical toothbrush)
Number of subjects: 25
Study 2465709 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg hydromorphone with 1/200,000 epinephrine (N = 15)
Number of subjects: 30
Study 2465709 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg hydromorphone alone (N = 15)
Number of subjects: 30
Study 31856912 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan dose-escalated FOLFIRI according to UGT1A1 genotyping plus 120 mg regorafenib
Number of subjects: 0
Study 31856912 — intervention group
Group type: COMPARATOR
Intervention: 120 mg regorafenib alone
Number of subjects: 0
Study 27033552 — intervention group
Group type: EXPERIMENTAL
Intervention: No-ventilation group (intubation tube detached from the ventilator)
Number of subjects: 47
Study 27033552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume group (continuous low tidal volume ventilation)
Number of subjects: 47
Study 27033552 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 10 cm H2O positive airway pressure
Number of subjects: 47
Study 27033552 — intervention group
Group type: COMPARATOR
Intervention: Patients without cardiopulmonary bypass (referral group)
Number of subjects: 47
Study 25557853 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg once a day for a month
Number of subjects: 80
Study 25557853 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg once a day for a month
Number of subjects: 80
Study 24176253 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First with Intensive Case Management (HF-ICM)
Number of subjects: 497
Study 24176253 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First with Assertive Community Treatment (HF-ACT)
Number of subjects: 497
Study 24176253 — intervention group
Group type: EXPERIMENTAL
Intervention: Congregate housing with support
Number of subjects: 497
Study 24176253 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 497
Study 21235425 — intervention group
Group type: EXPERIMENTAL
Intervention: Median or lateral umbilicus ligament covering the internal hernia opening region after laparoscopic purse‐string knot
Number of subjects: 428
Study 21235425 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic purse‐string knot closing the internal hernia opening only
Number of subjects: 428
Study 19755362 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management by health care assistants
Number of subjects: 626
Study 19755362 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 626
Study 17225705 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection for stages I through IIIA non-small cell carcinoma
Number of subjects: 0
Study 17225705 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality approach including radiotherapy, chemotherapy, and palliative care for advanced non-small cell carcinoma
Number of subjects: 0
Study 17225705 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (combined with radiotherapy for limited disease) for small cell carcinoma
Number of subjects: 0
Study 17225705 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 0
Study 15065952 — intervention group
Group type: EXPERIMENTAL
Intervention: Written disclosure condition
Number of subjects: 0
Study 15065952 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 11265023 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyHeme (up to 20 units)
Number of subjects: 0
Study 11265023 — intervention group
Group type: COMPARATOR
Intervention: PRBCs
Number of subjects: 0
Study 9778003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 15
Study 9778003 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of salbutamol
Number of subjects: 15
Study 9778003 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of salbutamol and intravenous lidocaine
Number of subjects: 15
Study 9778003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7980747 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical H2-blocker treatment (group 2)
Number of subjects: 414
Study 7980747 — intervention group
Group type: COMPARATOR
Intervention: Prompt endoscopy (group 1)
Number of subjects: 414
Study 3136677 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 500 micrograms and midazolam 5 mg
Number of subjects: 100
Study 3136677 — intervention group
Group type: COMPARATOR
Intervention: alfentanil 500 micrograms alone
Number of subjects: 100
Study 31238011 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium meal (HSM; 1495 mg Na+)
Number of subjects: 20
Study 31238011 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium meal (LSM; 138 mg Na+)
Number of subjects: 20
Study 30641326 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained inflation (15 seconds)
Number of subjects: 0
Study 30641326 — intervention group
Group type: COMPARATOR
Intervention: Routine UK practice (five inflations lasting 2 to 3 seconds)
Number of subjects: 0
Study 27572063 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Endoscopic Imaging (MEI)
Number of subjects: 246
Study 27572063 — intervention group
Group type: COMPARATOR
Intervention: Standard Colonoscopy (without MEI)
Number of subjects: 246
Study 25909681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenspiride (80 mg thrice daily)
Number of subjects: 80
Study 25909681 — intervention group
Group type: COMPARATOR
Intervention: Control group (antibacterial preparations, topical decongestants, glucocorticoids)
Number of subjects: 80
Study 22571977 — intervention group
Group type: EXPERIMENTAL
Intervention: DaTscan imaging
Number of subjects: 267
Study 22571977 — intervention group
Group type: COMPARATOR
Intervention: Control group without imaging
Number of subjects: 267
Study 21888757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS) 110 μg once daily for 2 weeks
Number of subjects: 363
Study 21888757 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 363
Study 17607120 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 35 mg/m2 IV on days 1, 8, and 15, and cisplatin 80 mg/m2 IV on day 15, every 4 weeks for four cycles
Number of subjects: 27
Study 17607120 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 IV plus cisplatin 80 mg/m2 IV on day 1 every 3 weeks for four cycles
Number of subjects: 27
Study 16305726 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (3-Impact Powder)
Number of subjects: 31
Study 16305726 — intervention group
Group type: COMPARATOR
Intervention: Omega-6 fatty acids (6-Impact Powder)
Number of subjects: 31
Study 11810600 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC removal
Number of subjects: 21
Study 9866064 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg aspirin from day 2 of the cycle through pregnancy testing
Number of subjects: 36
Study 9866064 — intervention group
Group type: COMPARATOR
Intervention: No aspirin (Control)
Number of subjects: 36
Study 7637874 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (alpha 2-adrenergic antagonist)
Number of subjects: 0
Study 7637874 — intervention group
Group type: COMPARATOR
Intervention: Morphine (postoperative intravenous)
Number of subjects: 0
Study 10295702 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural information (5-min tape recorded message)
Number of subjects: 30
Study 10295702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory information (5-min tape recorded message)
Number of subjects: 30
Study 10295702 — intervention group
Group type: COMPARATOR
Intervention: No information (control group)
Number of subjects: 30
Study 10295702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory information
Number of subjects: 30
Study 183943 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (180 and 360 mg daily)
Number of subjects: 90
Study 183943 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 90
Study 29392960 — intervention group
Group type: EXPERIMENTAL
Intervention: IL2/IFN/BEV
Number of subjects: 118
Study 29392960 — intervention group
Group type: COMPARATOR
Intervention: IL2/IFN
Number of subjects: 118
Study 27185571 — intervention group
Group type: EXPERIMENTAL
Intervention: QGE031 (240 mg every 2 weeks for 10 weeks)
Number of subjects: 37
Study 27185571 — intervention group
Group type: COMPARATOR
Intervention: Omalizumab
Number of subjects: 37
Study 27185571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 23890196 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous serum diluted with sodium hyaluronate
Number of subjects: 26
Study 23890196 — intervention group
Group type: COMPARATOR
Intervention: Autologous serum diluted with saline
Number of subjects: 26
Study 22715966 — intervention group
Group type: EXPERIMENTAL
Intervention: MoVo-LISA intervention group
Number of subjects: 220
Study 20013579 — intervention group
Group type: EXPERIMENTAL
Intervention: Early minimal enteral feeding (MEF) initiated at <= 5 days; median age: 2 days (range: 1 to 5 days)
Number of subjects: 84
Study 20013579 — intervention group
Group type: COMPARATOR
Intervention: Delayed minimal enteral feeding (MEF) initiated at >= 6 days; median age: 7 days (range: 6 to 14 days)
Number of subjects: 84
Study 18550253 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia-based all-ceramic fixed partial dentures with inlay retainers
Number of subjects: 30
Study 18550253 — intervention group
Group type: EXPERIMENTAL
Intervention: Different resin cements used for adhesion
Number of subjects: 30
Study 18550253 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque accumulation on abutment teeth
Number of subjects: 30
Study 18550253 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative sensitivity
Number of subjects: 30
Study 18550253 — intervention group
Group type: EXPERIMENTAL
Intervention: Aesthetic and functional performance of FPDs
Number of subjects: 30
Study 16037180 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL of 1.5% lidocaine containing 15 mug of epinephrine IV
Number of subjects: 80
Study 16037180 — intervention group
Group type: COMPARATOR
Intervention: 3 mL of saline IV
Number of subjects: 80
Study 12727307 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz TENS
Number of subjects: 16
Study 12727307 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz TENS
Number of subjects: 16
Study 12727307 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency TENS (100 Hz)
Number of subjects: 16
Study 10759733 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthetic cream (containing lignocaine and prilocaine) followed by local anaesthetic infiltration
Number of subjects: 53
Study 10759733 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 53
Study 8613046 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (12.5 mg once weekly for 9 months)
Number of subjects: 67
Study 8613046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 1358484 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous bolus injections of 100 micrograms octreotide every 8 hours
Number of subjects: 6
Study 1358484 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of the same daily dose of octreotide
Number of subjects: 6
Study 1358484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both bolus and continuous infusion treatment
Number of subjects: 6
Study 4013628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal block (i.c.b.) and centrally acting analgesics on demand
Number of subjects: 417
Study 4013628 — intervention group
Group type: COMPARATOR
Intervention: Centrally acting analgesics alone
Number of subjects: 417
Study 4013628 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral i.c.b. following cholecystectomy and choledocholithotomy
Number of subjects: 417
Study 4013628 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral i.c.b. given after surgery through a midline incision
Number of subjects: 417
Study 4013628 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-dependent analgesic demand
Number of subjects: 417
Study 4013628 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers receiving i.c.b.
Number of subjects: 417
Study 4013628 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of treatment with centrally acting analgesics
Number of subjects: 417
Study 31584141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring-based intervention (Campus Connections)
Number of subjects: 238
Study 28857909 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (sprint interval training)
Number of subjects: 26
Study 28857909 — intervention group
Group type: COMPARATOR
Intervention: MICT (moderate-intensity continuous training)
Number of subjects: 26
Study 27820648 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of traditional Chinese medicine and Western medicine
Number of subjects: 60
Study 27820648 — intervention group
Group type: COMPARATOR
Intervention: Western medicine treatment
Number of subjects: 60
Study 23149467 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar percutaneous approach
Number of subjects: 76
Study 23149467 — intervention group
Group type: COMPARATOR
Intervention: Dorsal limited approach
Number of subjects: 76
Study 22895080 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycinin soymilk (LGS, 49.5% β‐conglycinin/6% glycinin)
Number of subjects: 64
Study 22895080 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional soymilk (S, 26.5% β‐conglycinin/38.7% glycinin)
Number of subjects: 64
Study 22895080 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine milk (M, 0% β‐conglycinin/0% glycinin)
Number of subjects: 64
Study 20816841 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone with low cortisol
Number of subjects: 0
Study 20816841 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone with high cortisol
Number of subjects: 0
Study 20816841 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone after social threat (social defeat)
Number of subjects: 0
Study 20816841 — intervention group
Group type: EXPERIMENTAL
Intervention: High cortisol with higher testosterone
Number of subjects: 0
Study 17224178 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily injectable recombinant GH for 9 months
Number of subjects: 2006
Study 17224178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2006
Study 16125525 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (Flu) administered for 6 weeks
Number of subjects: 0
Study 12163783 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor intravenously in a 1-hr infusion, starting with 6000 IU, followed by 3000 IU, 2000 IU, and 1000 IU at 12-hr intervals
Number of subjects: 40
Study 12163783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10357404 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined paclitaxel (50 mg/m2/dose), cisplatin (15 mg/m2/dose), and etoposide (40 mg/m2/dose) administered twice weekly for 3 weeks, repeated every 28 days.
Number of subjects: 25
Study 10357404 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with or without concomitant 5-fluorouracil after chemotherapy.
Number of subjects: 25
Study 10357404 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 25
Study 8951506 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide therapy
Number of subjects: 0
Study 8951506 — intervention group
Group type: EXPERIMENTAL
Intervention: Active metabolite of leflunomide, A77 1726
Number of subjects: 0
Study 8951506 — intervention group
Group type: EXPERIMENTAL
Intervention: A77 1726
Number of subjects: 0
Study 1984883 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium reinjection after stress-redistribution imaging
Number of subjects: 16
Study 1984883 — intervention group
Group type: COMPARATOR
Intervention: PET imaging with FDG
Number of subjects: 16
Study 6189695 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (4 g)
Number of subjects: 20